Description: Avalo Therapeutics is a leading clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. The company has built a diverse portfolio of innovative therapies to deliver meaningful medical impact for patients in urgent need. The company’s clinical candidates commonly have a proven mechanistic rationale, biomarkers and/or an established proof-of-concept to expedite and increase the probability of success.
Home Page: www.avalotx.com
AVTX Technical Analysis
540 Gaither Road
Rockville,
MD
20850
United States
Phone:
410 522 8707
Officers
| Name | Title |
|---|---|
| Dr. Garry A. Neil M.D. | Chairman, Pres & CEO |
| Dr. Solomon H. Snyder M.D. | Founder and Chairman of Scientific Advisory Board |
| Dr. Barbara S. Slusher Ph.D. | Founder and Member of Scientific Advisory Board |
| Mr. Christopher Ryan Sullivan | Chief Financial Officer |
| Dr. Lisa Hegg Ph.D. | Sr. VP of Program Management & Corp. Infrastructure |
| Mr. Maxim Jacobs C.F.A. | VP of Investor Relations |
| Dr. Stephen Thomas Ph.D. | VP & Head of Discovery |
| Ms. Colleen Matkowski | Sr. VP of Global Regulatory Affairs & Quality Assurance |
| Dr. Dino C. Miano Ph.D. | Sr. VP of CMC & Technical Operations |
| Dr. Blake M. Paterson M.D. | Scientific Advisor |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.8996 |
| Price-to-Sales TTM: | 3.159 |
| IPO Date: | 2015-11-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 42 |